Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CytomX Therapeutics (CTMX) EBT (2016 - 2025)

CytomX Therapeutics (CTMX) has disclosed EBT for 12 consecutive years, with -$14.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBT fell 344.45% year-over-year to -$14.2 million, compared with a TTM value of $28.3 million through Sep 2025, up 87.66%, and an annual FY2024 reading of $32.1 million, up 865.78% over the prior year.
  • EBT was -$14.2 million for Q3 2025 at CytomX Therapeutics, down from -$90000.0 in the prior quarter.
  • Across five years, EBT topped out at $23.6 million in Q1 2025 and bottomed at -$34.8 million in Q4 2021.
  • Average EBT over 5 years is -$8.2 million, with a median of -$6.5 million recorded in 2024.
  • Peak annual rise in EBT hit 893.6% in 2024, while the deepest fall reached 496.32% in 2024.
  • Year by year, EBT stood at -$34.8 million in 2021, then surged by 74.8% to -$8.8 million in 2022, then surged by 121.72% to $1.9 million in 2023, then surged by 893.6% to $18.9 million in 2024, then tumbled by 174.83% to -$14.2 million in 2025.
  • Business Quant data shows EBT for CTMX at -$14.2 million in Q3 2025, -$90000.0 in Q2 2025, and $23.6 million in Q1 2025.